- Home
- /
- Treatment
- /
- Page 29
Treatments
The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.
You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.
Become a Partner.
| Country | Product | Indication | Sponsor | Date |
|---|---|---|---|---|
|
Temozolomide | Glioma | Double Bond Pharmaceutical AB | August 29, 2016 |
|
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]-phenyl}-2-oxo-acetamide | Scedosporiosis | F2G Ltd | August 29, 2016 |
|
Zoledronic acid | Glioma | Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.p.A. | August 29, 2016 |
|
Anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single domain antibody | Pancreatic Cancer | Singh Biotechnology, LLC;4708 Rue Bordeaux;Lutz, Florida, 33558 | August 29, 2016 |
|
Adenovirus associated viral vector serotype 5 containing the humanRPGRgene | Retinitis pigmentosa | MeiraGTx UK II Limited | August 29, 2016 |
|
Autologous mesenchymal stromal cells on a decellularised tracheal scaffold from a cadaveric donor | Tracheal stenosis | Videregen Ltd | August 29, 2016 |
|
Cannabidiol | Graft Versus Host Disease | Richardson Associates Regulatory Affairs Ltd | August 29, 2016 |
|
Cisplatin | Malignant pleural mesothelioma | PlumeStars s.r.l. | August 29, 2016 |
|
L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser | Prevention of graft loss in pancreatic islet transplantation | Araim Pharma Europe Ltd | August 29, 2016 |
|
6′-(R)-methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)-paromamine sulfate | Hurler syndrome | Coté Orphan Consulting UK Limited | August 29, 2016 |
|
Recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues | Glycogen storage disease type II (Pompe’s disease) | NanoMedSyn | August 29, 2016 |
|
Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene | Duchenne muscular dystrophy | Pfizer Limited | August 29, 2016 |
|
Ublituximab | Neuromyelitis optica | TG Therapeutics, Inc.;3 Columbus Circle, 15th Floor;New York, New York, 10019 | August 25, 2016 |
|
Recombinant, fully-human, IgG4 immunoglobulin with antigen-binding specificity for human vascular adhesion protein-1 (VAP-1) | Primary sclerosing cholangitis | Acorda Therapeutics, Inc.;420 Saw Mill River Road;Ardsley, New York, 10502 | August 25, 2016 |
|
Phosphoinositide-3-kinase delta inhibitor | Chronic lymphocytic leukemia | TG Therapeutics, Inc.;3 Columbus Circle, 15th Floor;New York, New York, 10019 | August 23, 2016 |
|
Etrolizumab | Ulcerative colitis | Genentech, Inc.;1 Dna Way;South San Francisco, California, 94080 | August 22, 2016 |
|
Nivolumab | Esophageal cancer | Bristol-Myers Squibb Co.;5 Research Parkway;Wallingford, Connecticut, 06492 | August 22, 2016 |
|
Cultured skin substitute (CSS) | Burns requiring skin grafting | Regenicin Inc.;10 High Court;Little Falls, New Jersey, 07424 | August 22, 2016 |
|
(1,3)-�-D-glucan synthesis inhibitor | Invasive Aspergillus infections | SCYNEXIS, Inc.;101 Hudson Street, Suite 3610;Jersey City, New Jersey, 07302 | August 22, 2016 |
|
Disufenton sodium | Glioblastoma | Oblato, Inc.;116 Village Boulevard;Princeton, New Jersey, 08540 | August 22, 2016 |
|
(1,3)-ß-D-glucan synthesis inhibitor | Invasive Aspergillus infections | SCYNEXIS, Inc.;101 Hudson Street, Suite 3610;Jersey City, New Jersey, 07302 | August 22, 2016 |
|
Live E. coli Nissle bacterium modified to assimilate ammonia | Urea cycle disorders | Synlogic, Inc.;200 Sidney Street, #320;Cambridge, Massachusetts, 02139 | August 22, 2016 |
|
Ambrisentan/tadalafil fixed combination | Pulmonary Arterial Hypertension | Gilead Sciences, Inc.;333 Lakeside Drive;Foster City, California, 94404 | August 22, 2016 |
|
Stabilized sulforaphane | Subarachnoid hemorrhage | Evgen Pharma PLC;146 Brownlow Hill;Liverpool | August 22, 2016 |
|
Rituximab and recombinant human hyaluronidase | Chronic lymphocytic leukemia | Genentech, Inc.;1 DNA Way;South San Francisco, California, 94080 | August 22, 2016 |
